Saturday 17 October 2026
Export AXGN’s income statement to Excel — free account
AxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024. In the quarter to June 2026, revenue grew 23.1%, EPS fell 400.0%, free cash flow fell 17.4% and total debt fell 72.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
34.62
1.01
−2.83%
Follow AXGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
9.81 | 7.18 | 6.69 | 3.86 | |
P/FCF ratio |
378.46 | 223.17 | 0.00 | 402.65 | |
P/Operating CF |
341.19 | 1,092.16 | 496.12 | 257.36 | |
P/B ratio |
9.61 | 6.98 | 11.70 | 6.87 | |
Price to Tangible BV |
9.91 | 7.20 | 12.34 | 7.25 | |
EV/Sales |
9.44 | 6.83 | 6.79 | 3.99 | |
EV/EBITDA |
0.00 | 3,460.14 | 986.66 | 69.78 | |
EV/Operating CF |
157.54 | 104.54 | 1,883.41 | 131.72 | |
EV/FCF |
364.14 | 212.33 | (319.81) | 416.18 | |
Quick Ratio |
4.86 | 5.07 | 3.04 | 2.52 | |
Current Ratio |
6.60 | 7.10 | 5.11 | 4.09 | |
Net Debt/EBITDA |
23,830.25 | 129.83 | (3.36) | 6.49 | |
Debt/Assets |
5.93% | 7.13% | 30.51% | 30.30% | |
Debt/Equity |
0.07 | 0.08 | 0.52 | 0.54 | |
Asset Turnover |
0.98 | 0.98 | 1.06 | 1.05 | |
Operating CF/Net income |
(4.76) | (0.08) | (0.23) | 4.55 | |
Capex/Depreciation |
(0.81) | (1.35) | (0.61) | (0.90) | |
Interest Coverage |
(2,156.00) | (4.08) | (5.69) | 1.09 | |
Research and Development Expense of Revenue |
12.32% | 12.23% | 20.66% | 12.59% | |
Selling, General and Administrative Expense of Revenue |
63.45% | 67.53% | 69.79% | 60.78% | |
Intangible Assets out of Total Assets |
0.02 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
12.57% | 11.13% | 27.73% | 9.03% | |
Graham Net Nets |
0.06 | 0.08 | 0.02 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.46%) | (1.92%) | (1.02%) | (0.25%) | |
Free Cash Flow Yield |
0.26% | 0.45% | (0.32%) | 0.25% | |
Revenue per Share |
1.31 | 1.19 | 1.30 | 1.29 | |
Operating CF per Share |
0.14 | 0.03 | 0.07 | 0.07 | |
Capex per Share |
(0.03) | (0.06) | (0.04) | (0.04) | |
Free Cash Flow per Share |
0.10 | (0.03) | 0.02 | 0.03 | |
Cash per Share |
2.13 | 2.01 | 0.99 | 0.86 | |
Shareholders Equity per Share |
4.80 | 4.75 | 2.80 | 2.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.80 | 4.75 | 2.80 | 2.60 | |
Free Cash Flow |
5.47 | (1.40) | 1.08 | 1.36 | |
Working Capital |
170.00 | 158.70 | 96.87 | 86.45 | |
Capital Expenditures |
(1.75) | (2.96) | (1.96) | (1.86) | |
Net Current Asset Value |
151.77 | 140.03 | 27.58 | 18.86 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 217.60 | |
Capex to Sales |
0.03 | 0.05 | 0.03 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 210.52 | |
| Other line items | |||||
Average Receivables |
31.08 | 27.30 | 25.14 | 27.70 | |
Average Payables |
25.58 | 21.78 | 24.91 | 23.42 | |
Average Inventory |
42.04 | 40.79 | 37.78 | 34.97 | |
Average Assets |
255.16 | 242.83 | 212.71 | 204.19 | |
Average Common Equity |
184.27 | 175.09 | 116.38 | 110.11 |
Columns are period end dates